NLS Pharmaceutics AG's (NLSP) stock saw a notable increase of 29.79 percent, during Friday morning trading. This surge follows the ...

The Dow traded down 0.04% to 44,865.23 while the NASDAQ climbed 1.15% to 19,908.53. The S&P 500 also rose, gaining, 0.57% to 6,105.94. Exxon Mobil Corporation XOM reported better-than-expected ...

NLS Pharmaceutics stock is trading higher on Friday after the company announced its merger with Kadimastem has been approved by Kadimastem shareholders.

NLS Pharmaceutics Ltd. (NASDAQ: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous system ...

Kadimastem’s attempt to vault onto Nasdaq is picking up momentum, with shareholders signing off on a merger with NLS Pharmaceutics that would enable the cell therapy developer to recover from last ...

ZURICH and NESS ZIONA, Israel - Shareholders of Kadimastem Ltd. (TASE: KDST), a cell therapy company currently valued at $18.19 million, have approved a merger with Swiss biopharmaceutical firm NLS ...

NLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development ...

NLS Pharmaceutics (NLSP) and Kadimastem, a clinical-stage cell therapy company specializing in the treatment of neurodegenerative diseases and ...

NLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and ...

NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system ...

The Ahmedabad -based Patel, whose Zydus Group runs a chain of multi-specialty hospitals, further said, “We are taking a leap ...

Innovation from India will bring critical access to affordable healthcare and empower people to lead healthier and more ...